Latest News-CliniExpert

NIH Halts Clinical Trial of Hydroxychloroquine

June 20, 2020 -- A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has been stopped by t

FDA Approves Cabenuva (cabotegravir and rilpivirine) Long-Acting Injectable HIV Treatment and Vocabria (cabotegravir) Oral HIV Treatment

London, 21 January 2021 -- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that

GSK COVID-19 Vaccine Development Collaboration with Clover Biopharmaceuticals Begins Clinical Trials

London, UK June 19, 2020 -- GSK’s scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover today announced the init

GSK Announces FDA Advisory Committee Meeting to Review Belantamab Mafodotin for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

London UK - 19 June 2020 -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to rev

Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate

Perth, AUSTRALIA and Chengdu, CHINA – 19 June 2020 -- Clover Biopharmaceuticals today announced that the first participants have been dosed in the Phase 1 first-in-human study evaluating the company’s

Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19

MIAMI--(BUSINESS WIRE)--June 19, 2020 -- Ridgeback Biotherapeutics announces the launch of two Phase 2 clinical trials to test the efficacy of EIDD-2801 as an anti-viral treatment for COVID-19. Phase

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following Giroctocogene Fitelparvovec (SB-525) Gene Therapy

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE) June 18, 2020 -- Pfizer Inc. (NYSE:PFE)andSangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data

Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer

London: Thursday, June 18, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation

Genentech’s IPATential150 Study Evaluating Ipatasertib in Combination With Abiraterone and Prednisone/Prednisolone Met One of Its Co-Primary Endpoints

South San Francisco, CA -- June 18, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IPATential150 study met its co-primary endpoint of r

FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction

KENILWORTH, N.J.--(BUSINESS WIRE) -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Verquvo, a solub

CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate

TÜBINGEN, Germany/ BOSTON -- June 17, 2020 -- CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that th

BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit

SAN RAFAEL, Calif., June 17, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today additional data from its previously reported four-year update of an open-label Phase 1/2 s